/
J Clin Oncol
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial
- C.W. Scholz
- A. Pinto
- W. Linkesch
- O. Lindén
- A. Viardot
- U. Keller
- G. Hess
- S. Lastoria
- K. Lerch
- F. Frigeri
- M. Arcamone
- A. Stroux
- B. Frericks
- C. Pott
- A. Pezzutto